logo

Citius Pharmaceuticals Inc (CTXR) Stock: A Year of Highs and Lows

The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Citius Pharmaceuticals Inc’s current trading price is -58.82% away from its 52-week high, while its distance from the 52-week low is 10.25%. The stock’s price range for this period has been between $0.48 and $1.28 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 1.4 million for the day, a number notably lower than the average daily volume of 1.88 million over the last three months.

Citius Pharmaceuticals Inc saw a rather unpredictable run in, in terms of market performance. The company’s stock reached its highest point at $1.28 on 07/18/23, while the lowest price for the same duration was marked at $0.48 on 07/03/24.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis

Citius Pharmaceuticals Inc (CTXR) has experienced a quarterly decline of -44.19% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 95.61M and boasts a workforce of 22 employees.

Analyzing Trading Volume and Moving Average Trends

Based on Barchart.com data, the company’s moving average over the 100-day period was 0.7229, with a change in price of -0.1288. Similarly, Citius Pharmaceuticals Inc recorded 1,458,206 in trading volume during the last 100 days, posting a change of -19.57%.

Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis

The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for CTXR stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.

CTXR Stock Stochastic Average

Citius Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 13.30%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 20.67%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 8.40% and 5.59%, respectively.

CTXR Stock Price Performance Analysis

A mixed performance in the stock price over the year has left investors unsure of what to expect, resulting in a range of outlooks from optimistic to pessimistic. This year’s metric has recorded a Price decrease of -30.05%. However, over the past six months, we’ve seen a stronger performance of -32.41%. The price of CTXR leaped by -17.05% over the last 30 days. And in the last five days, it has fallen by -17.08%.

Most Popular